<DOC>
	<DOCNO>NCT02201940</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy , safety , tolerability sofosbuvir/velpatasvir ( SOF/VEL ) fix dose combination ( FDC ) 12 week adults chronic genotype 1 , 2 , 4 , 5 , 6 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed Dose Combination 12 Weeks Adults With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing able provide write informed consent HCV RNA ≥ 10^4 IU/mL screen HCV genotype 1 , 2 , 4 , 5 , 6 , indeterminate assess screening central laboratory Chronic HCV infection ( ≥ 6 month ) document prior medical history liver biopsy Classification treatment naive treatment experience Males female childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception Current prior history clinicallysignificant illness ( HCV ) major medical disorder may interfere treatment , assessment , compliance protocol ; individual currently evaluation potentially clinicallysignificant illness ( HCV ) also exclude . Screening ECG clinically significant abnormality Laboratory result outside acceptable range Screening Prior exposure SOF nucleotide analogue HCV NS5B inhibitor HCV NS5A inhibitor Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Sofosbuvir</keyword>
	<keyword>SOF/VEL</keyword>
	<keyword>Velpatasvir</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>cirrhosis</keyword>
</DOC>